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Introduction
The earliest reports on the therapeutic use of
metals and metal containing compounds in cancer
and leukaemia date back to the sixteenth century.
They were forgotten until 1960s when antitumour
activity of inorganic cis-diamminedichloroplatinum(II)
(cisplatin) was discovered (1). Numerous other metal
compounds were shown to be effective against
tumours up to date (2).
Polyoxometallates (POMs) are a huge group of
complex inorganic compounds with a great variety of
uses (analytical reagents, catalysts, superionic proton
conductors, sensors, membranes in fuel cells, etc.).
There are two main classes of POMs: the isopolycom-
pounds that contain only d metal and oxygen atoms
as anion and heteropoly compounds that contain one
or more p, d or f ’ block heteroatoms in addition (3).
As heteropoly compounds are more numerous and
their structural properties are easier to modify synthe-
tically, this family of POMs dominates the medically
oriented research and uses up to date  (4). Several ge-
neral attributes of POMs such as polarity, redox poten-
tial, surface charge distribution, shape and acidity,
render them attractive for usage in medicine (4).
Structurally, heteropoly compounds can be of diffe-
rent types, but most of them with biological issues
have common Keggin's structure.
The first biological activity of POM was reported
in 1971, when Raynaud noted that polytungstosilicate
heteropoly compounds inhibited murine leukaemia
sarcoma virus in vitro (5). Prior to 1990, in vitro stu-
dies conducted by various groups showed the efficien-
cy of POMs against several viruses: vesicular stomati-
tis, polio, rubella, Rausher leukaemia, rhabdovirus, etc
(4). Today, there is a lot of data about antiviral activity,
especially agains HIV virus (6). Although the mode of
antiviral action has been well documented, the primary
mechanism remained elusive. The most likely of all
the proposed mechanisms are inhibition of viral en-
zymes (reverse transcriptase and/or protease in retro-
viruses) or surface viral proteins, such as gp120 for
HIV (4).
Contrary to numerous data on antiviral activity,
there is a limited information about POMs antitumoral
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Summary: The antitumour action of three polyoxometallate compounds of Keggin's type: 12-molibdo-
phosphoric acid (MoPA), 12-tungstophosphoric acid (WPA) and Mg salt of WPA  (MgHWPA) was studied in vitro.
For human cervix carcinoma (HeLa) cells survival, as well as for nonstimulated and stimulated peripheral blood
mononuclear cells (PBMC), MTT test was applied and IC50 values of POMs were determinated.  Index selectivity
for WPA and MgHWPA are 1.9 and 1.8, calculated for nonstimulated, as well as 2.5 and 2.0, calculated for sti-
mulated PBMS. Combination of studied POMs do not contribute to their lower IC50 values. Apoptosis detection
implies mild cytotoxic effect of WPA and more cytostatical effect of MgHWPA. Combination of each of the stu-
died POMs with caffeine decreases HeLa survival in dose dependent way. None of the studied POMs in the used
concentrations (up to 100 mmol/L) damages blood cells and/or decreases their number.
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activity. Among POMs, only some complex derivates
of 12-molibdophosphoric acid have been reported as
agents with antitumour activity (4). The only mecha-
nism of in vivo antitumour activity, proposed by Ya-
mase (7), revolves around a single electron reduction/
oxidation cycle, where POMs reoxidation and tumour
cell reduction process kill the cells.
The aim of the present article was to study in
vitro antitumour effects of 12-molibdophosphoric
acid, H3PMo12O40 (MoPA), and 12-tungstophosphoric
acid, H3PW12O12 (WPA), both with common Kegin's
structure.
Another compound suitable for such an investi-
gation was Mg salt of WPA, MgHPW12O40 (MgHWPA).
Introducing Mg2+ in WPA structure, antitumour effects
could be considerably improved. It is already known
that magnesium defficiency can paradoxically protect
against oncogenesis (8). Over 300 enzymes that influ-
ence the metabolism of carbohydrates, amino acids,
nucleic acids and proteins, and also regulate ion trans-
port, require Mg.  It has been proposed that Mg is cen-
tral in the cell cycle, and that its deficiency is an impor-
tant conditioner in precancerous cell transformation
(9’12).
Since the principal disadvantage of POMs is their
high toxity (renal toxity, hepatotoxicity and thrombocy-
topenia), in vitro experiments of these POMs in blood
cells in the periferial blood, were also performed.
Material and Methods
MoPA, WPA and MgHWPA were synthezided in
the way described earlier (13). The thermal analysis,
IR, and SEM examinations for compound characteri-
zation were performed. The content of Mg in MgHWPA
was determined by AAS (14). 
In order to study the antitumour effects, MoPA,
WPA and MgHWPA were tested in vitro on human
cervix carcinoma cells (HeLa cells) under the same
conditions, and the obtained effects were compared.
Antitumuor-test 
Chemicals. Stock solutions of examined com-
pounds were made in water at concentrations of 10
mmol/L and afterwards diluted by nutrient medium to
various final concentrations (in the range  25’200, or
0.01’100 mmol/L). The 3-(4,5-dimethyl-thiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) and RPMI
1640 cell culture medium were purchased from Sigma
Chemicals (St. Luis, MO, U.S.A.). MTT was dissolved,
5 mg/mL in phosphate buffer saline of pH= 7. 2, and
filtered through millipore filter, 0. 22 mm, before use.
Cell culture. Human cervix carcinoma, HeLa
cells, were maintained as a monolayer culture, in the
nutrient medium (RPMI 1640 medium supplemented
with L-glutamine (3 mmol/L), streptomycin (100
mg/mL), and penicillin (100 IU/mL), 10% heat inacti-
vated foetal bovine serum, FBS and 25 mmol/L He-
pes, adjusted to pH= 7. 2 by bicarbonate solution).
The cells were grown at 37 ‰C in humidified air atmos-
phere with 5% CO2.
Treatment of HeLa cells. Target cells were see-
ded in 0.1 mL of nutrient medium into one group of
96-well microtiter plates, 2000 cells per well. After
twenty hours of cell seeding, solutions of various con-
centrations of examined compounds were added to
the wells, except to the control wells where only nutri-
ent medium was added. All samples were done in trip-
licate. Nutrient medium with corresponding agents
concentrations but without target cells, was used as
blank, also in triplicate.
Preparation of peripheral blood mononuclear
cells. PBMC were separated from the whole hepa-
rinised blood of healthy volunteers by LymphoprepTM
gradient centrifugation.  Interface cells, washed three
times with HaemaccelÒ aqueous solution supplemen-
ted with 145 mmol/L Na+, 5.1 mmol/L K+, 6.2
mmol/L Ca2+, 145 mmol/L Cl’ and 35 g/L gelatine
polymers, pH=7.4, were counted and resuspended in
nutrient medium.
Treatment of PBMC. Target cells were seeded
(100,000 cells per well) into nutrient medium and in
nutrient medium enriched with 5 mg/mL phytohae-
magglutinin, PHA, (Welcome) in 96-well microtiter
plates and two hours later, five different concentrations
of compounds were added to PBMC in triplicates (to
the same final concentrations used for treatment of
malignant cells) except to the control wells where a
nutrient medium was added to the cells. Nutrient me-
dium with corresponding concentrations of compo-
unds, but void of cells was used as blank.
Determination of target cell survival.  Cell sur-
vival was determined by MTT test according to the
method of Mosmann (15) and modified by Ohno and
Abe (16), 72 hours after the drug addition. Briefly, 20
mL of MTT solution (5 mg/mL PBS) was added to
each well.  Samples were incubated for further four ho-
urs at 37 °C in humid-ified atmosphere with 5% CO2.
Then, 100 mL of 10% SDS was added to the wells.
Absorbance was measured at 570 nm the next day. To
get cell survival (%), absorbance at 570 nm of a sam-
ple with cells grown in the presence of various con-
centrations of agent (A), was divided with absorbance
of control group (AC, the absorbance of cells grown
only in nutrient medium), implying that absorbance of
blank was always subtracted from absorbance of a
corresponding sample with target cells.  
Apoptosis detection. HeLa cells were seeded on
cover slips (3 × 105 cells) in 2 mL of complete medi-
um (RPMI-1640 supplemented with 10% heat inacti-
vated FCS) and, after 24 h, were treated with 100
mmol/L of WPA or MgHWPA for 2 days. After 24 h or
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48 h of continuous agents action, cells were stained
with 15 mL of acridine orange/ethidium bromide (3
g/mL AO and 10 g/mL EB in PBS) and visualized
under a fluorescence microscope using blue filter. 
Effects of POMs on blood cells
Assessment was performed in citrate human
peripheral blood from healthy donors. The standard
routine procedure for determination of the number of
blood cells on cell counter  (HMX ’ »Coulter«) was
used. The volumes of 3 mL of blood and 0.3 mL of
100 mmol/L of each sample of POMs were mixed. The
effect of dilution was eliminated by adding correspon-
ding amounts of physiological solution instead of
POMs.
Results
Results of in vitro antitumour activity of investi-
gated POMs on HeLa cells as well as on stimulated
and nonstimulated PBMC is presented in Table I.
Value IC50 presents the effective concentration of the
agent (POM) required for inhibition of cell survival by
50% compared with control. The antitumour effect of
different POMs was expressed through selectivity index
obtained as ratio of IC50 for nonstimulated or stimulat-
ed PBM cells and of IC50 for HeLa cells.
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Compound
MoPA
WPA
MgHWPA
HeLa cells
169
74
84
IC50, mmol/L Selectivity index
PBMC
>100
141
151
PBMC + PHA
>100
183
167
PMBC/HeLa
/
1.9
1.8
PMBC+PHA/HeLa
/
2.5
2.0
Table I   Values of IC50 and selectivity index for the activity of examined POMs on HeLa and PBMC, 
determined by MTT test, 72 h after the continuous agent action
Figure 1.   Acridine orange and ethidium bromide stained HeLa cells incubated in nutrient medium alone (A, B), 
or with 100 mmol/L of WPA after 24h (C) and 48h (D) 
or with 100 mmol/L of MgHWPA after 24h (E) and 48h ( F). 
A B C
D E F
From Table I, it can be seen that the antiprolif-
erative effect of MoPA on HeLa cells is insignificant,
while it was mild for WPA and MgHWPA. The toxicity
of all examined POMs, followed through IC50 on
PBMC and stimulated PBMC, is relatively low.
The combination of POMs does not significantly
contribute to their better antitumour action.  Namely,
synergetic effect of WPA and MoPA results in IC50
=133 mmol/L on HeLa cells while the same effect of
combination of WPA and MgHWPA results in lower
value of IC50 =84 mmol/L.
HeLa cells incubated in nutrient medium with
100 mmol/L of WPA and MgHWPA for 24 h and 48 h
are presented in Figure 1. It can be seen that HeLa
cells viability was not affected 24h after the continuous
WPA action, although some flattened cells were seen.
The appearance of few necrotic (orange) cells is obser-
ved 48h after the start of cells treatment. Continuous
MgHWPA action did not change viability of examined
cells, although some detachment of treated cells co-
uld be noticed.  
The effect of examined POMs together with caf-
feine on HeLa cells, was determined, since it has been
reported that this combination has antitumour effect
in vivo (17). Results are presented in histogram (Fi-
gure 2). Figure 2 shows that pretreatment of HeLa
cells with caffeine alone decreases their survival in
dose dependent way. Combination of each of exam-
ined POMs with caffeine added 72 h after caffeine,
contributes to further decrease of cell survival for next
48 h.
Results of the effect of examined POMs on num-
ber of blood cells (red-RBC, white-WBC and platelet-
PLT) from peripheral blood are presented in Table II.
From Table II, it is evident that none of the examined
POMs causes decrease in the number and/or dam-
ages blood cells The last was confirmed by micro-
scopic examination of the peripheral blood cells
films.
Discussion
Examined POMs show no considerable effects
on HeLa cells survival tested in vitro: effect of MoPA
is insignificant, WPA has a mild cytotoxic effect and
MgHWPA acted more cytostatically, what is evident
from Figure 1. Evaluation of promising antitumour
agent in vitro usually results in high therapeutic (selec-
tivity) index (>5 for antiviral action) (4). In our study
this index is the ratio of IC50 for normal (PBMC) and
malignant (HeLa) cells, and ranges from 1.8 to 2.5.
Although our examined POMs are not in compliance
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RBC
×1012/L
4.58
4.10
4.11
4.17
4.13
WBC
×109/L
9.26
8.24
8.29
8.47
8.22
PLT × 109/L
171
153
167
149
166
Blood 
(healthy donor)
Blank
MoPA
WPA
MgHWPA
Table II   Effects of MoPA, WPA and MgHWPA
(c=100 mmol/L) on various peripheral blood cells counts,
determined by blood cell counter, 
2h after the continuous agent action
Figure 2.   The effect of 40 mmol/L of WPA, MgHWPA, 
and MoPA on HeLa cells, pretreated with 0.0 mmol/L (A), 
0.5 mmol/L (B) and 1 mmol/L(C) of caffeine for 72h.  
Cell survival was determined by MTT test, 
72 h after the continuous agent action.
120
100
80
60
40
20
0
S%
A             B             C
Caffeine
Caff.+WPA
120
100
80
60
40
20
0
S%
A             B             C
Caffeine
Caff.+MgHWPA
120
100
80
60
40
20
0
S%
A             B             C
Caffeine
Caff.+MoPA
with this ratio, their action in vivo could be expected
to be more prominent. It was already confirmed that
POMs antiviral activity in vivo differs from activity in
vitro, because POMs can penetrate cell membranes
and thus localize intracellulary (4). 
In early sexteen it was reported, the combination
of MoPA, WPA and caffeine in patients with non-
metastatic carcinoma of the intestinal tract results in
total tumour disappearance. From our results, the
antiproliferative effect of caffeine alone is evident, and
some enhancement of its action in the presence of
POMs do exist. Therefore it could be supposed that
the antiproliferative action of the mentioned agent
combinations could be enhanced in vivo, taking into
account that caffeine is a compound with known com-
plex pharmacological activity. 
It should be pointed out that POMs in concen-
trations which exert cytotoxic effect on HeLa cells do
not modify the number and morfology of blood cells.
This implies that  this concentration range of POMs is
suitable for their probable use.
Although the obtained in vitro results of antitu-
mour effect of POMs are not remarkable, the further in
vivo studies with WPA and MgHWPA should be rea-
sonable. In order to improve the anticancer action of
WPA and to decrease its toxicity, the modification of
this compound with organic molecule (amino acid) is
in progress.
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Kratak sadr`aj: Ispitivano je in vitro antitumorsko dejstvo tri jedinjenja iz grupe polioksometalata (POM-a)
Keginovog tipa: 12-fosformolibdenska kiselina (MoPA), 12-fosforvolframova kiselina (WPA) i Mg so 12-fosforvol-
framove kiseline (MgHWPA).  Primenom  MTT testa na }elije karcinoma cerviksa (HeLa }elije), kao i na nestimuli-
sane i stimulisane mononuklearne }elije iz periferne krvi (PBMC), odre|ene su  IC50 vrednosti ispitivanih POM-a.
Indeksi selektivnosti za WPA i MgHWPA su 1,9 i 1,8 ra~unati za nestimulisane, odnosno 2,5 i 2,0 za stimulisane
PBMC. Kombinacijom ispitivanih POMa ne posti`e se smanjenje njihovih IC50 vrednosti.  Detekcijom apoptoze
utvr|eno je da  WPA pokazuje blagi citotoksi~ni efekat, dok MgHWPA ima blagi citotostatski efekat. U kombinaciji
sa kofeinom, POM jedinjenja jo{ vi{e smanjuju pre`ivljavanje HeLa }elija. U ispitivanim koncentracijama (do 100
mmol/L), nijedno od POM jedinjenja ne uti~e na broj i izgled krvnih }elija pune krvi zdravih davalaca. 
Klju~ne re~i: polioksometalati, antitumorsko dejstvo, HeLa }elije 
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